Cyclerion Therapeutics (CYCN) FCF Margin (2019 - 2025)
Cyclerion Therapeutics (CYCN) posted FCF Margin of 30.17% for Q3 2025, up 94.42% on a QoQ basis from 540.86% in Q2 2025, and up 85436.0% year-over-year from N/an in Q3 2024.
Powered by 
Analysis
Cyclerion Therapeutics (CYCN) FCF Margin (2019 - 2025) Analysis & Trends
Cyclerion Therapeutics has reported FCF Margin for 6 years, with the latest figure at 30.17% in Q3 2025.
- On a quarterly basis, FCF Margin rose 85436.0% year-over-year to 30.17% in Q3 2025; TTM through Sep 2025 was 48.16%, a 316524.0% increase from a year earlier, with the FY2024 full-year figure at 216.65%, changed N/A from the prior year.
- FCF Margin was 30.17% for Q3 2025 at Cyclerion Therapeutics, up from 540.86% in the prior quarter.
- The five-year high for FCF Margin was 19.93% in Q4 2024, with the low at 23167.74% in Q1 2021.
- Average FCF Margin over 4 years is 3193.55%, with a median of 1195.06% recorded in 2025.
- The sharpest annual moves came in 2021 and 2022: FCF Margin tumbled 2015147 bps in 2021, then surged 2137534 bps in 2022.
- Over 4 years, FCF Margin stood at 1601.88% in 2021, then sank by 119 bps to 3505.23% in 2022, then jumped by 101 bps to 19.93% in 2024, then plunged by 251 bps to 30.17% in 2025.
- The last three FCF Margin figures came in at 30.17% (Q3 2025), 540.86% (Q2 2025), and 1195.06% (Q1 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.70% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 44.00% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 30.39% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 13.35% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -388.28% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 22.62% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 14.91% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -18,629.40% |
| 10 | Cyclerion Therapeutics | 15.70 Mn | 12.46 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -30.17% |
| Jun 30, 2025 | -540.86% |
| Mar 31, 2025 | -1,195.06% |
| Dec 31, 2024 | 19.93% |
| Sep 30, 2024 | -884.54% |
| Jun 30, 2022 | -3,505.23% |
| Mar 31, 2022 | -1,792.41% |
| Dec 31, 2021 | -1,601.88% |
| Sep 30, 2021 | -2,250.57% |
| Jun 30, 2021 | -180.57% |
| Mar 31, 2021 | -23,167.74% |
| Dec 31, 2020 | -10,583.46% |
| Sep 30, 2020 | -3,764.25% |
| Jun 30, 2020 | -1,908.68% |
| Mar 31, 2020 | -3,016.27% |
| Dec 31, 2019 | -1,508.24% |
| Sep 30, 2019 | -1,750.00% |
| Jun 30, 2019 | -1,610.32% |